Compare BTMD & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTMD | BYSI |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0M | 25.5M |
| IPO Year | 2021 | 2016 |
| Metric | BTMD | BYSI |
|---|---|---|
| Price | $0.84 | $0.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $2.22 | N/A |
| AVG Volume (30 Days) | 84.3K | ★ 127.4K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 722.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $192,219,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.95 | $49.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $0.42 |
| 52 Week High | $2.90 | $2.44 |
| Indicator | BTMD | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 32.21 | 38.95 |
| Support Level | N/A | $0.42 |
| Resistance Level | $1.24 | $0.85 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 2.85 |
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.